Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'Watch This Space' Roche Execs Say, Outlining RWE Rationale For Flatiron Buy

Executive Summary

Buying Flatiron Health offers research-quality electronic medical records data which will help gain access to patients and help in the drug development and reimbursement process, Roche exes say.

You may also be interested in...



Gilead Lures Roche Pharma CEO O'Day As CEO; Genentech's CEO Will Replace Him

O'Day brings Gilead experience in oncology and M&A from a large, diversified organization.

CEO Interview: Roche Pharma Head Daniel O'Day On R&D Strategy

In an interview with Scrip, Roche Pharma CEO Daniel O'Day emphasized the importance that personalized healthcare will have in transforming R&D and how patients are treated.

CEO Interview: Roche Pharma Head Daniel O'Day On R&D Strategy

In an interview with Scrip, Roche Pharma CEO Daniel O'Day emphasized the importance that personalized healthcare will have in transforming R&D and how patients are treated.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132972

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel